Since the beginning of the Modern Age, inventors and companies have sought to protect their innovations through patents — the legal instrument granting temporary exclusivity over their developments. In the pharmaceutical industry, this mechanism carries particular weight: research cycles are long, regulatory approval costs are high, and the commercial exclusivity window largely determines a product’s financial viability.
For those working in pharmaceutical development — whether as innovators seeking to protect their technology or as companies exploring the generics space — understanding how intellectual property works and what strategies exist to navigate that environment is a critical competency.
A Brief History of Patents: From Henry VI to Modern Pharma
The first European patent was granted on March 19, 1449, by King Henry VI of England to John of Utynam, a Flemish glassmaker, giving him a 20-year monopoly over his manufacturing process. In the United States, the first patent dates to 1790, granted to Samuel Hopkins for a potash manufacturing method. Since then, over 3 million active patents have been granted in the European Economic Community alone, and more than 11 million in the United States.
What began protecting relatively simple ideas has evolved into a system of extreme technical specificity. In the last 25 years, many patents represent minimal incremental contributions within the same field of study — known as atomization of the patentable space — generating complex webs of protection over a single product.
Benefits and Limitations of Patents: Both Sides of the Equation
Benefits for the patent holder | Limitations for the ecosystem |
|---|---|
Exclusive rights: allows the owner to exclude others from making, using, selling or importing the invention without authorization. | Restricted access: limits access to new technologies and knowledge, potentially delaying research. |
Competitive advantage: protects the invention from competition during the protection period. | High costs: obtaining and maintaining a patent demands significant financial and time resources. |
Income generation: possibility of licensing the patent or selling it to third parties. | Barriers to collaboration: can hinder cooperation and information exchange between scientists and institutions. |
Innovation incentive: promotes R&D investment by guaranteeing a potential return. | Incremental innovation: can encourage conservative improvements rather than disruptive advances. |
Market value: increases company value and attracts investors. | Monopoly risk: although international protection measures exist, patents can generate commercial monopolies. |
Requirements for Obtaining a Pharmaceutical Patent
For a pharmaceutical invention to be patentable, it must meet five conditions:
- Novelty: the invention must be new and not have been publicly disclosed before the application.
- Inventive step: must involve a step that is not obvious to someone with knowledge in the field.
- Industrial application: must be useful and applicable in industry or commerce.
- Sufficient description: the application must include a detailed description enabling others to reproduce it.
- Clear claims: must precisely define the scope of the requested protection.
A patent grants a protection period of 20 years. In the pharmaceutical field, specific mechanisms exist that allow extending that term by up to 5 additional years, compensating for long regulatory approval timelines.
The Particular Scenario of Transdermal Patches: Patent Complexity and Development Opportunities
In the pharmaceutical industry, virtually no new drugs, processes, devices, or treatments reach the market without patent protection. Long regulatory approval timelines and high research costs make this strategy the norm, not the exception.
The transdermal patch segment presents a particularly complex scenario. It is one of the pharmaceutical formats where the most patents simultaneously protect the same product — generally with incremental inventive contributions — generating an intricate technical space that is difficult to interpret.
However, this complexity is not only an obstacle. It also creates opportunities. The specificity and punctuality of protected claims frequently leaves technical space outside the scope of infringement, where it is possible to develop an equivalent product that:
- Does not infringe any active patent of the innovator product.
- Is industrially feasible, safe, efficacious, and stable.
- Can even obtain its own patent on the alternative technical solution.
In the transdermal segment, there are generic products that do not infringe innovator patents and that hold their own granted patents.
The key to navigating this scenario is finding vulnerabilities in the claims of associated patents, defining a viable technical workspace, and verifying whether — with components, processes, and devices outside the protected space — it is technically feasible to develop a product equivalent to the reference product.
This analysis requires specialized technical capability in transdermal formulation, deep knowledge of the intellectual property framework, and accumulated experience in the segment’s patent landscape. It is not an analysis that can be performed generically.
Amarin’s Perspective: Innovator and Generic Developer Simultaneously
Amarin Technologies operates on both sides of this scenario simultaneously.
On one side, it holds proprietary patents protecting its developments in Fentanyl, Buprenorphine, Rotigotine, Selegiline, and Rivastigmine patches. These patents represent years of R&D investment and are part of the differential value Amarin brings to its partners in out-licensing and co-development models.
On the other side, Amarin continuously faces the challenge of developing generics that circumvent patents associated with reference products, with the goal of being competitive and reaching the market on time. This dual capability — protecting proprietary innovation and navigating third-party intellectual property — is one of the most valuable assets Amarin brings to its partners.
If your company is evaluating the development of a generic transdermal patch or the licensing of technology in this segment, contact us at info@amarintech.com.ar to analyze the applicable intellectual property landscape for your project.
